(Q44006991)

28 November 2017

title

Improved fibrinolysis after 1-year treatment with HMG CoA reductase inhibitors in patients with coronary heart disease (English)

1 reference

28 November 2017

3

Ingvar Hjermann

1 reference

28 November 2017

Ingebjørg Seljeflot

1

1 reference

28 November 2017

Serena Tonstad

series ordinal

2

1 reference

28 November 2017

Harald Arnesen

series ordinal

4

1 reference

28 November 2017

language of work or name

1 reference

1 February 2002

1 reference

28 November 2017

1 reference

28 November 2017

volume

105

1 reference

28 November 2017

issue

4

1 reference

28 November 2017

page(s)

285-290

1 reference

The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial investigators

28 November 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2802%2900034-8

7 January 2021

Prevention of Cardiovascular Events and Death with Pravastatin in Patients with Coronary Heart Disease and a Broad Range of Initial Cholesterol Levels

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2802%2900034-8

7 January 2021

Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2802%2900034-8

7 January 2021

Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. Air Force/Texas Coronary Atherosclerosis Prevention Study

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2802%2900034-8

7 January 2021

Effects of lipid lowering by pravastatin on progression and regression of coronary artery disease in symptomatic men with normal to moderately elevated serum cholesterol levels. The Regression Growth Evaluation Statin Study (REGRESS)

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2802%2900034-8

7 January 2021

Statins do more than just lower cholesterol

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2802%2900034-8

7 January 2021

Fibrinolytic activity, clotting factors, and long-term incidence of ischaemic heart disease in the Northwick Park Heart Study

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2802%2900034-8

7 January 2021

Predictive value of tissue plasminogen activator mass concentration on long-term mortality in patients with coronary artery disease. A 7-year follow-up

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2802%2900034-8

7 January 2021

Hemostatic factors and the risk of myocardial infarction or sudden death in patients with angina pectoris. European Concerted Action on Thrombosis and Disabilities Angina Pectoris Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2802%2900034-8

7 January 2021

Hypertriglyceridaemia and hypercoagulability

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2802%2900034-8

7 January 2021

ECAT angina pectoris study: baseline associations of haemostatic factors with extent of coronary arteriosclerosis and other coronary risk factors in 3000 patients with angina pectoris undergoing coronary angiography

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2802%2900034-8

7 January 2021

Treatment with hydroxymethylglutaryl-coenzyme A reductase inhibitors in hypercholesterolemia induces changes in the components of the extrinsic coagulation system

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2802%2900034-8

7 January 2021

Inhibition of thromboxane biosynthesis and platelet function by simvastatin in type IIa hypercholesterolemia

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2802%2900034-8

7 January 2021

Effect of Fluvastatin on Lipids and Fibrinolysis in Coronary Artery Disease

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2802%2900034-8

7 January 2021

Randomized placebo-controlled study of the effects of simvastatin on haemostatic variables, lipoproteins and free fatty acids. The Oxford Cholesterol Study Group.

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2802%2900034-8

7 January 2021

Pravastatin therapy in hyperlipidemia: effects on thrombus formation and the systemic hemostatic profile

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2802%2900034-8

7 January 2021

Antiatherothrombotic properties of statins: implications for cardiovascular event reduction

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2802%2900034-8

7 January 2021

Low-density lipoprotein-independent effects of statins

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2802%2900034-8

7 January 2021

The evolving role of statins in the management of atherosclerosis

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2802%2900034-8

7 January 2021

[Rapid physiological coagulation method in determination of fibrinogen]

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2802%2900034-8

7 January 2021

Effects of lovastatin therapy on plasminogen activator inhibitor-1 antigen levels

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2802%2900034-8

7 January 2021

Stimulating effect of oxidized low density lipoproteins on plasminogen activator inhibitor-1 synthesis by endothelial cells

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2802%2900034-8

7 January 2021

Cholesterol lowering and endothelial function

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2802%2900034-8

7 January 2021

Effect of atorvastatin and fluvastatin on the expression of plasminogen activator inhibitor type-1 in cultured human endothelial cells

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2802%2900034-8

7 January 2021

Endogenous tissue-type plasminogen activator and risk of myocardial infarction

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2802%2900034-8

7 January 2021

Atorvastatin: an effective lipid-modifying agent in familial hypercholesterolemia

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2802%2900034-8

7 January 2021

Inhibition of tissue-factor-mediated thrombin generation by simvastatin

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2802%2900034-8

7 January 2021

Role of platelets in tissue factor expression by monocytes in normal and hypercholesterolemic subjects. In vitro effect of cerivastatin

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2802%2900034-8

7 January 2021

10.1016/S0049-3848(02)00034-8

Identifiers

DOI

1 reference

28 November 2017

1 reference